Liver Failure (Hepatic Insufficiency) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Liver Failure (Hepatic Insufficiency) – Pipeline Review, H1 2017’, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency)

The report reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Failure (Hepatic Insufficiency) therapeutics and enlists all their major and minor projects

The report assesses Liver Failure (Hepatic Insufficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Failure (Hepatic Insufficiency)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alfact Innovation

BioLineRx Ltd

Cell2B Advanced Therapeutics SA

Conatus Pharmaceuticals Inc

Immune Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Ocera Therapeutics Inc

PledPharma AB

Promethera Biosciences SA

Silence Therapeutics Plc

Unicyte AG

Ventria Bioscience

Vital Therapies Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Failure (Hepatic Insufficiency) - Overview

Liver Failure (Hepatic Insufficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development

Alfact Innovation

BioLineRx Ltd

Cell2B Advanced Therapeutics SA

Conatus Pharmaceuticals Inc

Immune Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Ocera Therapeutics Inc

PledPharma AB

Promethera Biosciences SA

Silence Therapeutics Plc

Unicyte AG

Ventria Bioscience

Vital Therapies Inc

Liver Failure (Hepatic Insufficiency) - Drug Profiles

ALF-5755 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit FAS for Liver Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit MKK4 for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-1220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-573 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImmuneSafe - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTL-CEBPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silibinin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEN-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Failure (Hepatic Insufficiency) - Dormant Projects

Liver Failure (Hepatic Insufficiency) - Discontinued Products

Liver Failure (Hepatic Insufficiency) - Product Development Milestones

Featured News & Press Releases

Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial

Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases

Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan

Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting

Apr 11, 2013: Gene inhibition helps to improve liver regeneration

Apr 02, 2013: ALF-5755 phase II completion

Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury

Sep 04, 2012: Ventria Bioscience And University Of Colorado Receive NIH Grant To Study Treatment Of Acetaminophen Overdose-Induced Liver Failure

Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure

May 06, 2011: ALF-5755 phase II extends to germany

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Alfact Innovation, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by BioLineRx Ltd, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Cell2B Advanced Therapeutics SA, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Mina Therapeutics Ltd, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Mylan NV, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Ocera Therapeutics Inc, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by PledPharma AB, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Promethera Biosciences SA, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Silence Therapeutics Plc, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Unicyte AG, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Ventria Bioscience, H1 2017

Liver Failure (Hepatic Insufficiency) – Pipeline by Vital Therapies Inc, H1 2017

Liver Failure (Hepatic Insufficiency) – Dormant Projects, H1 2017

Liver Failure (Hepatic Insufficiency) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports